TomoTherapy (TOMO) Reports Q3 Loss of $0.27; Guides
More News related to TOMO
- Study Indicates Potential for Reduction in TomoTherapy (TOMO) Treatment Time With Improved Radiation Therapy Plan Quality
- TomoTherapy (TOMO) Could Reduce TomoTherapy Time by 66% With Advanced Radiation Delivery Techniques
- Study Indicates Potential for Dramatic Reduction in TomoTherapy(SM) Treatment Time With Improved Radiation Therapy Plan Quality
- TomoTherapy to Present at Piper Jaffray Health Care Conference
- ASTRO Presentations Highlight Role of TomoTherapy(R) Technology in Combined Modality Approach to Treating Cancer
More News related to Earnings
- Randgold Resources (GOLD) Raises Stake in Tongon Mine to 89%
- Bloomingdale's Chairman Sees Jewelry Sales Up 20% at the End of November, Calls Consumer 'Confident'
- Highlights From TIF's Q3 Conference Call: Sales Declines, But Less-Than-Expected; Raises FY Outlook
- A123 Systems (AONE) Enters MEGA Tax Credit Agreement with Michigan Economic Growth Authority
- Starbucks (SBUX) Bets Big On China
TomoTherapy Incorporated (NASDAQ: TOMO) reports Q3 loss of $0.27, versus the analyst estimate of $0.20. Revenue for the quarter was $34.40 million, which compares to the estimate of $40.28 million.
Sees Q4 loss $0.6 - $0.23, versus $0.14 previously
Related Categories
EarningsGuidance
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
